close
  • Approved Use: Aimovig® (erenumab-aooe) is a prescription medicine used for the preventive treatment of migraine in adults.

You are now leaving aimovig.com

You are about to leave the aimovig.com website and enter a website operated by a third party. Amgen is not responsible for and does not endorse or control the content contained on this third-party website.

Continue

You are now leaving aimovig.com

You are about to leave the aimovig.com website and enter a website operated by a third party. Amgen & Novartis are not responsible for and do not endorse or control the content contained on this third-party website.

Continue
  1. Access to americanmigrainefoundation.org is not intended to provide medical advice or a referral to a particular physician;
  2. Patients should discuss with their physician their experience with the patient’s medical condition and should then determine if the physician is qualified to perform the procedure;
  3. Patients should discuss the risks and benefits of any procedure with their physician;
  4. americanmigrainefoundation.org is an independent entity, and not affiliated with, or an agent of, Amgen Inc.
  5. Amgen Inc. has not entered into any agreement with any doctor affiliated with americanmigrainefoundation.org to render any treatment or care to any patient, and has not evaluated the credentials, experience or expertise of any physician affiliated with, or referred through, americanmigrainefoundation.org.
  6. AMGEN INC. MAKES NO EXPRESS, IMPLIED OR STATUTORY WARRANTIES OR REPRESENTATIONS (INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE) AMERICANMIGRAINEFOUNDATION.ORG. TO THE MAXIMUM EXTENT PERMITTED BY LAW, AMGEN INC. AND ITS AFFILIATES ARE NOT RESPONSIBLE FOR AND EXPRESSLY DISCLAIM ALL LIABILITY, INCLUDING WITHOUT LIMITATION, FOR DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, AND SPECIAL OR OTHER DAMAGES ARISING FROM OR RELATED TO THE USE OF ANY SERVICES OFFERED BY AMERICANMIGRAINEFOUNDATION.ORG. BY ACCESSING AMERICANMIGRAINEFOUNDATION.ORG, YOU AGREE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW THAT YOU WILL HOLD AMGEN INC. AND ITS AFFILIATES HARMLESS FROM ANY AND ALL CLAIMS ARISING FROM OR IN CONNECTION WITH ANY ACT OR OMISSION OF AMERICANMIGRAINEFOUNDATION.ORG.

You are now leaving aimovig.com

You are about to leave the aimovig.com website and enter a website operated by a third party. Amgen Inc. is not responsible for and does not endorse or control the content contained on this third-party website.

Click “OK” to proceed or “CANCEL” to return to aimovig.com

By clicking “OK” below, you acknowledge that you have read and reviewed the information contained within the Notice of Third-Party Site at the bottom of the page.

OK CANCEL
I am...ready to learn more about Aimovig®

Aimovig® helps prevent monthly migraine days before they start.

one dose, once a month is designed to keep working 24/7, to help reduce monthly migraine days

One dose, once a month is designed to keep working 24/7, to help reduce monthly migraine days.

For some, it cuts monthly migraine days by

For some, it cuts migraine days by 50% or more

*In a clinical study, Months 4-6.

Ellen, a real Aimovig® patient who states "with fewer monthly migraine days, I can participate in life with my family more often now. My migraine used to be so frequent, I couldn’t be there as much with themEllen, a real Aimovig® patient who states "with fewer monthly migraine days, I can participate in life with my family more often now. My migraine used to be so frequent, I couldn’t be there as much with them

Meet Ellen

“With fewer monthly migraine days, I can participate in life with my family more often now. My migraine used to be so frequent, I couldn’t be there as much with them.”

Real patient. Individual results may vary.

In clinical trials, Aimovig® was proven to help prevent monthly migraine days in both chronic and episodic migraine patients.

Chronic Migraine

~7
fewer days
on average

In a 3-month study

People with chronic migraine* taking Aimovig® experienced ~7 fewer monthly migraine days on average (vs ~4 for placebo).

Chronic migraine patients had around 7 fewer days on average with a 50% or more reduction in monthly migraine days. Chronic migraine patients had around 7 fewer days on average with a 50% or more reduction in monthly migraine days.

~40% of people with chronic migraine* taking Aimovig® cut their monthly migraine days by 50% or more (vs ~24% for placebo).

*Chronic migraine is defined as 15 or more headache days per month, at least 8 of which were migraine days.

Episodic Migraine

3-4
fewer days
on average

In a 6-month study

People with episodic migraine† taking Aimovig® experienced 3 to 4 fewer monthly migraine days on average (vs ~2 for placebo).

Episodic migraine patients had 3–4 fewer days on average and a 50% or more reduction in monthly migraine days. Episodic migraine patients had 3–4 fewer days on average and a 50% or more reduction in monthly migraine days.

Up to 50% of people with episodic migraine† taking Aimovig® cut their monthly migraine days by 50% or more (vs ~27% for placebo).

†Episodic migraine is defined as 4 to 14 migraine days per month.

+ +

Important Safety Information

Who should not use Aimovig®? Do not use Aimovig® if you are allergic to erenumab-aooe or any ingredients in Aimovig®. Before starting Aimovig®, tell your healthcare provider (HCP) about all your medical conditions, including if you have high blood pressure, have circulation problems in your fingers and toes, are pregnant or plan to become pregnant, are breastfeeding or plan to breastfeed. Tell your HCP about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements.
 
–

Important Safety Information

Who should not use Aimovig®? Do not use Aimovig® if you are allergic to erenumab-aooe or any ingredients in Aimovig®. Before starting Aimovig®, tell your healthcare provider (HCP) about all your medical conditions, including if you have high blood pressure, have circulation problems in your fingers and toes, are pregnant or plan to become pregnant, are breastfeeding or plan to breastfeed. Tell your HCP about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements. What are possible side effects of Aimovig®? Aimovig® may cause serious side effects, including:
  • Allergic reactions. Allergic reactions, including rash or swelling can happen after receiving Aimovig®. This can happen within hours to days after using Aimovig®. Call your HCP or get emergency medical help right away if you have any of the following symptoms of an allergic reaction: swelling of the face, mouth, tongue or throat, or trouble breathing.
  • Constipation with serious complications. Severe constipation can happen after receiving Aimovig®. In some cases people have been hospitalized or needed surgery. Contact your HCP if you have severe constipation or constipation associated with symptoms such as severe or constant belly pain, vomiting, swelling of belly or bloating.
  • High blood pressure. High blood pressure or worsening of high blood pressure can happen after receiving Aimovig®. Contact your healthcare provider if you have an increase in blood pressure.
  • Raynaud's Phenomenon. A type of circulation problem can worsen or happen after receiving AIMOVIG. Raynaud’s phenomenon can lead to your fingers or toes feeling numb, cool, or painful, or changing color from pale, to blue, to red. Contact your healthcare provider if these symptoms occur
The most common side effects of Aimovig® are pain, redness, or swelling at the injection site and constipation. These are not all of the possible side effects of Aimovig®. Call your HCP for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Click here for the full Prescribing Information and Patient Product Information.

APPROVED USE

Aimovig® (erenumab-aooe) is a prescription medicine used for the preventive treatment of migraine in adults.
References: 1. Parsabiv® (etelcalcetide) prescribing information, Amgen. 2. Data on file, Amgen; [Summary of Clinical Efficacy; 2015]. 3. Alexander ST, et al. Mol Pharmacol. 2015;88:853-865. 4. Data on file, Amgen; [Report R20130052, 2014]. 5. Chen P, et al. CPT Pharmacometrics Syst Pharmacol. 2016;5:484-494. 6. Sensipar® (cinacalcet) prescribing information, Amgen. 7. Ma JN, et al. J Pharmacol Exp Ther. 2011;337:275-284.
+ +

Important Safety Information

Who should not use Aimovig? Do not use Aimovig if you are allergic to erenumab-aooe or any ingredients in Aimovig®